文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

右美托咪定改善严重脓毒症患者的肾功能:一项随机对照试验的探索性分析

Dexmedetomidine improved renal function in patients with severe sepsis: an exploratory analysis of a randomized controlled trial.
PubMed 文献 · J Intensive Care · 2020-01-02
一句话结论在APACHE II≥23的严重脓毒症机械通气患者中,含右美托咪定的镇静策略与第4天肾脏SOFA子评分显著下降及28天和住院死亡率降低相关。

本研究为DESIRE随机对照试验的探索性亚分析,纳入日本8个ICU中201例机械通气成人脓毒症患者中的104例APACHE II≥23者(右美托咪定组54例,非右美托咪定组50例)。比较随机化后6天内SOFA评分变化,并进一步分析初始比较中显示相关改善的器官组分变量。结果发现右美托咪定组第4天肾脏SOFA子评分显著下降(p=0.02),6天内血清肌酐显著更低(p=0.04),28天死亡率(22% vs 42%;p=0.03)和住院死亡率(28% vs 52%;p=0.01)显著更低。结论认为含右美托咪定的镇静策略与严重脓毒症患者肾功能改善和死亡率降低相关。

要点

  • 在APACHE II≥23的严重脓毒症机械通气患者中,右美托咪定组第4天肾脏SOFA子评分较基线显著下降(p=0.02)。
  • 随机化后6天内,右美托咪定组血清肌酐水平显著低于非右美托咪定组(p=0.04),但尿量无显著差异(p=0.09)。
  • 右美托咪定组28天死亡率22% vs 非右美托咪定组42%(p=0.03),住院死亡率28% vs 52%(p=0.01),均显著更低。
  • 两组基线中位APACHE II评分无差异(29 vs 30;p=0.35),但右美托咪定组基线中位SOFA评分更低(9 vs 11;p=0.01)。

适用人群与场景

  • 日本8个ICU中机械通气成人脓毒症患者,本分析纳入APACHE II评分≥23者104例(右美托咪定组54例,非右美托咪定组50例)。
  • 来自DESIRE试验(比较含与不含右美托咪定的镇静策略)的探索性亚分析人群。

诊断标准与关键阈值

  • 严重脓毒症诊断依据原DESIRE试验入选标准,本分析额外要求APACHE II评分≥23。
  • 肾脏SOFA子评分基线两组相似,第4天右美托咪定组显著下降(p=0.02)。

研究设计与关键结果

  • 研究类型:随机对照试验的探索性亚分析;样本量104例(右美托咪定组54例,非右美托咪定组50例);日本8个ICU;人群为APACHE II≥23的机械通气成人脓毒症患者。
  • 干预与对照:含右美托咪定的镇静策略 vs 不含右美托咪定的镇静策略。
  • 主要终点结果:6天内SOFA评分变化中,右美托咪定组第4天肾脏SOFA子评分显著下降(p=0.02);6天内尿量无显著差异(p=0.09),但血清肌酐显著更低(p=0.04)。
  • 关键次要终点:28天死亡率右美托咪定组22% vs 非右美托咪定组42%(p=0.03);住院死亡率28% vs 52%(p=0.01),均显著更低。
  • 基线特征:平均年龄71.0±14.1岁;中位APACHE II评分两组无差异(29 [IQR 25-31] vs 30 [IQR 25-33];p=0.35);中位SOFA评分右美托咪定组更低(9 [IQR 7-11] vs 11 [IQR 9-13];p=0.01)。

证据类型、等级与局限

  • 证据类型:随机对照试验的探索性亚分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,含右美托咪定的镇静策略与严重脓毒症患者肾功能改善和死亡率降低相关。
  • 本分析为探索性亚分析,结果需结合原DESIRE试验解读。

指南或共识出处

  • DESIRE试验(Dexmedetomidine for Sepsis in Intensive Care Unit Randomized Evolution),ClinicalTrials.gov注册号NCT01760967,注册日期2013年1月1日。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Dexmedetomidine has been reported to improve organ dysfunction in critically ill patients. In a recent randomized controlled trial (Dexmedetomidine for Sepsis in Intensive Care Unit (ICU) Randomized Evolution [DESIRE]), we demonstrated that dexmedetomidine was associated with reduced mortality risk among patients with severe sepsis. We performed this exploratory sub-analysis to examine the mechanism underlying improved survival in patients sedated with dexmedetomidine.

METHODS: The DESIRE trial compared a sedation strategy with and without dexmedetomidine among 201 mechanically ventilated adult patients with sepsis across eight ICUs in Japan. In the present study, we included 104 patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores of ≥ 23 (54 in the dexmedetomidine [DEX] group and 50 in the non-dexmedetomidine [non-DEX] group). Initially, we compared the changes in the sequential organ failure assessment (SOFA) scores from the baseline within 6 days after randomization between groups. Subsequently, we evaluated the variables comprising the organ component of the SOFA score that showed relevant improvement in the initial comparison.

RESULTS: The mean patient age was 71.0 ± 14.1 years. There was no difference in the median APACHE II score between the two groups (29 [interquartile range (IQR), 25-31] vs. 30 [IQR, 25-33]; p = 0.35). The median SOFA score at the baseline was lower in the DEX group (9 [IQR, 7-11] vs. 11 [IQR, 9-13]; p = 0.01). While the renal SOFA subscore at the baseline was similar for both groups, it significantly decreased in the DEX group on day 4 (p = 0.02). During the first 6 days, the urinary output was not significantly different (p = 0.09), but serum creatinine levels were significantly lower (p = 0.04) in the DEX group. The 28-day and in-hospital mortality rates were significantly lower in the DEX group (22% vs. 42%; p = 0.03, 28% vs. 52%; p = 0.01, respectively).

CONCLUSION: A sedation strategy with dexmedetomidine is associated with improved renal function and decrease mortality rates among patients with severe sepsis.

TRIAL REGISTRATION: This trial was registered on ClinicalTrials.gov (NCT01760967) on January 1, 2013.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Nakashima T, Miyamoto K, Shima N, et al. Dexmedetomidine improved renal function in patients with severe sepsis: an exploratory analysis of a randomized controlled trial. J Intensive Care. 2020. PMID: 31908779. doi:10.1186/s40560-019-0415-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。